Protective Effects of Levetiracetam and Simvastatin on Pilocarpine-induced Epilepsy in Rat Models

LI Meng-qiu, ZHANG Wen-wu, CHEN Tao. et al

Abstract

To determine neuroprotective properties of levetiracetam and simvastatin using rats with pilocaroine-induced epilepsy. Methods Epileptic rat models were randomly divided into 4 groups, each being exposed to saline, simvastatin, levetiracetam, or levetiracetam+simvastatin. Brain tissues of the rats were examined. Nissl staining was used to determine pilocarpine-induced neuronal loss in CA1 and CA3 of hippocampus. Western blot was used to detect calpain-1 expression of hippocampus. Results Severe cell death was found 24 h after seizures, with a level significantly higher than the controls. Compared with the saline-treated cells, simvastatin did not decrease severe cell death (\P>0.05), but levetiracetam and levetiracetam+simvastatin decreased severe cell death 24 h after seizures (\P<0.05). No significant differences were found between those treated with levetiracetam and those with levetiracetam+simvastatin. Compared with controls, overexpressed calpain-1 was found in the rats 24 h after seizures, which indicates that calpain-1 may be involved in the pathophysiological mechanisms of epilepsy. Compared with those treated with pilocarpine+saline, simvastatin, levetiracetam and levetiracetam+simvastatin reduced the level of calpain-1 24 h after seizures (\P<0.05). Conclusion Levetiracetam, not simvastatin, possesses neuroprotective properties, through changing calpain-1 expression levels. But levetiracetam plus simvastatin treatment does not have advantages over the choice of monotherapy. Simvastain does not possess neuroprotective properties at the early stage of epilepsy.

 

Keywords: Status epilepsy, Hippocampus, SimvastatinLevetiracetam, Calpain-1 


Full Text:

PDF


References


Brophy GM, Bell R. Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care,2012;17(1) :3-23.

Nairismagi J, Grohn OH, Kettunen MI. et al. Progression of brain damage after status epilepticus and its association with epileptogenesis; a quantitative MRI study in a rat model of temporal lobe epilepsy. Epilepsia*2004 ;45(9): 1024-1034.

Arundine M, Tymianski M. Molecular mechanisms of calcium- dependent neurodegeneration in excitotoxicity. Cell Calcium,2003;34(4-5):325-337.

Rego AC. Oliveira CR. Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis; Implications for the pathogenesis of neurodegenerative diseases. Neurochem Res,2003;28(10);1563-1574.

Margineanu ЕЮ, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res, 2000; 42 (4) : 281- 285.

Zona C* Niespodziany I, Marchetti G,etaL. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure,2001; 10(4) ;279-286.

Niespodziany I. Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca2+ current in pyramidal neurones of rat hippocampal slices. Neurosci Lett , 2001; 306( 1- 2): 5-8.

Ma T, Zhao Y, Kwak YD,et al. Statin’s excitoprotection is mediated by sAPP and the subsequent attenuation of calpain- induced truncation events, likely via Rho-ROCK signaling. J Neurosci. 2009; 29( 36). 11226-11236.

Racine RJ. Modification of seizure activity by electricalstimulation, II : motor seizure. Electroencephalogr Clin Neurophysiol ,1972; 32; 281-294.

Xie C, Sun J. Qiao W. et al. Administration of simvastatin after kainic acid-induced status epilepticus restrains chronic temporal lobe epilepsy. PLoS One»2011;6(9) :e24966. doi:10. 1371/journal, pone. 0024966. Epub 2011 Sep 19.

Marini H- Costa С. Passaniti M-et al. Levetiracetam protects against kainic acid-induced toxicity. Life Sci. 2004; 74 ( 10 ): 1253-1264.

Stepien K, Tomaszewski M, Czuczwar SJ. Neuroprotective properties of statins. Pharmacol Rep,2005 ;57(5); 561-569.

Ramirez C, Tercero 1, Pineda A, et al. Simvastatin is the statin that most efficiently protects against kainate-induced excitotoxicity and memory impairment. J Alzheimers Dis,2011; 24(1);161-174.


Refbacks

  • There are currently no refbacks.